` 2197 (Clover Biopharmaceuticals Ltd) vs Hang Seng (Hong Kong) Comparison - Alpha Spread

C
2197
vs
H
Hang Seng (Hong Kong)

Over the past 12 months, Clover Biopharmaceuticals Ltd has significantly outperformed Hang Seng (Hong Kong), delivering a return of +497% compared to the Hang Seng (Hong Kong)'s +16% growth.

Stocks Performance
2197 vs Hang Seng (Hong Kong)

Loading
2197
Hang Seng (Hong Kong)
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
2197 vs Hang Seng (Hong Kong)

Performance Gap Between 2197 and HSI
HIDDEN
Show

Performance By Year
2197 vs Hang Seng (Hong Kong)

Loading
2197
Hang Seng (Hong Kong)
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Clover Biopharmaceuticals Ltd vs Peers

Hang Seng (Hong Kong)
2197
RYI
GLDD
AVGR
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Clover Biopharmaceuticals Ltd
Glance View

Market Cap
2.5B HKD
Industry
Biotechnology

Clover Biopharmaceuticals Ltd. engages in the research and development of biopharmaceutical products. The company is headquartered in Chengdu, Sichuan and currently employs 814 full-time employees. The company went IPO on 2021-11-05. The firm's main business is the development of new vaccines and biotherapeutic candidates for infectious diseases, cancer and autoimmune diseases. The firm's products are mainly used to treat the new coronavirus, malignant ascites, and ankylosing spondylitis.

Clover Biopharmaceuticals Ltd Intrinsic Value
HIDDEN
Show
Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett